Merck enters into exclusive global license with LaNova Medicines to develop, manufacture & commercialize LM-299, an investigational anti-PD-1/VEGF bispecific antibody

MLA

“Merck Enters into Exclusive Global License with LaNova Medicines to Develop, Manufacture & Commercialize LM-299, an Investigational Anti-PD-1/VEGF Bispecific Antibody.” PharmaBiz, Nov. 2024. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.816471555&authtype=sso&custid=ns315887.

APA

Merck enters into exclusive global license with LaNova Medicines to develop, manufacture & commercialize LM-299, an investigational anti-PD-1/VEGF bispecific antibody. (2024, November 16). PharmaBiz.

Chicago

PharmaBiz. 2024. “Merck Enters into Exclusive Global License with LaNova Medicines to Develop, Manufacture & Commercialize LM-299, an Investigational Anti-PD-1/VEGF Bispecific Antibody,” November 16. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.816471555&authtype=sso&custid=ns315887.